ZLAB

Zai Lab Ltd

Add to Watchlist

Advanced Chart

37.000

+2.34(6.751%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

38.410

Open

37.510

VWAP

37.35

Vol

1.76M

Mkt Cap

4.11B

Low

36.510

Amount

65.89M

EV/EBITDA(TTM)

Total Shares

98.72M

3.29B

EV/OCF(TTM)

P/S(TTM)

8.47

Zai Lab Ltd is a holding company primarily engaged in biopharmaceuticals. The Company is committed to addressing the unmet medical needs in the fields of tumors, autoimmune diseases, infectious diseases and central nervous system diseases through product discovery, development and commercialization. The Company has a series of patented drug candidates from the discovery stage to the late clinical project. These include ZEJULA, OPTUNE, QINLOCK, NUZYRA and VYVGART, and others.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2025Q3

FY2025Q2

183.91M

+68.61%

-0.128

-83.98%

153.68M

+50.28%

-0.291

-30.76%

125.02M

+24.39%

-0.415

-49.39%

Estimates Revision

The market is revising Upward the revenue expectations for Zai Lab Limited (ZLAB) for FY2025, with the revenue forecasts being adjusted by 0.43% over the past three months. During the same period, the stock price has changed by 13.74%.

Revenue Estimates for FY2025

Revise Upward

+0.43%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-14.16%

In Past 3 Month

Stock Price

Go Up

+13.74%

In Past 3 Month

7 Analyst Rating

53.24% Upside

Wall Street analysts forecast ZLAB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ZLAB is 56.70 USD with a low forecast of 38.20 USD and a high forecast of 75.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

6 Buy

1 Hold

0 Sell

Strong Buy

53.24% Upside

Current: 37.000

Low

38.20

Averages

56.70

High

75.00

53.24% Upside

Current: 37.000

Low

38.20

Averages

56.70

High

75.00

Cantor Fitzgerald

Li Watsek

Buy

Reiterates

n/a

2025-03-27

Reason

Cantor Fitzgerald

Li Watsek

Price Target

n/a

2025-03-27

Reiterates

Buy

Reason

JP Morgan

Anupam Rama

Buy

Maintains

$44 → $51

2025-03-13

Reason

JP Morgan

Anupam Rama

Price Target

$44 → $51

2025-03-13

Maintains

Buy

Reason

JPMorgan raised the firm's price target on Zai Lab to $51 from $44 and keeps an Overweight rating on the shares. The firm updated models in the small-cap biotechnology space.

Scotiabank

Louise Chen

Buy

Initiates

$55

2025-03-07

Reason

Scotiabank

Louise Chen

Price Target

$55

2025-03-07

Initiates

Buy

Reason

B of A Securities

David Lim

Strong Buy

Hold

Downgrades

$29 → $36

2025-03-03

Reason

B of A Securities

David Lim

Price Target

$29 → $36

2025-03-03

Downgrades

Strong Buy

Hold

Reason

Cantor Fitzgerald

Louise Chen

Buy

Reiterates

n/a

2024-10-25

Reason

Cantor Fitzgerald

Louise Chen

Price Target

n/a

2024-10-25

Reiterates

Buy

Reason

JP Morgan

Anupam Rama

Buy

Maintains

$38 → $44

2024-10-21

Reason

JP Morgan

Anupam Rama

Price Target

$38 → $44

2024-10-21

Maintains

Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Zai Lab Ltd (ZLAB.O) is -39.54, compared to its 5-year average forward P/E of -14.09. For a more detailed relative valuation and DCF analysis to assess Zai Lab Ltd 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-14.09

Current PE

-39.54

Overvalued PE

-3.59

Undervalued PE

-24.59

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-11.38

Current EV/EBITDA

-28.60

Overvalued EV/EBITDA

-3.08

Undervalued EV/EBITDA

-19.67

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

25.64

Current PS

5.70

Overvalued PS

56.07

Undervalued PS

-4.80

Financials

Annual

Quarterly

FY2025Q1

YoY :

+22.19%

106.49M

Total Revenue

FY2025Q1

YoY :

-19.91%

-56.31M

Operating Profit

FY2025Q1

YoY :

-9.41%

-48.44M

Net Income after Tax

FY2025Q1

YoY :

-20.00%

-0.04

EPS - Diluted

FY2025Q1

YoY :

-36.41%

-65.57M

Free Cash Flow

FY2025Q1

YoY :

+3.73%

63.71

Gross Profit Margin - %

FY2025Q1

YoY :

-25.86%

-45.49

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

8.8M

USD

3-6

Months

6.1M

USD

6-9

Months

204.4K

USD

0-12

Months

168.3K

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

64.6K

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

1.6M

Volume

Months

6-9

4.1M

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

8.8M

USD

3-6

Months

6.1M

USD

6-9

Months

204.4K

USD

0-12

Months

168.3K

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

ZLAB News & Events

Events Timeline

2025-06-30 (ET)

2025-06-30

09:17:51

Zai Lab announces FORTITUDE-101 clinical trial meets primary endpoint

2025-06-13 (ET)

2025-06-13

07:07:27

Zai Lab announces new data from preclinical study of ZL-1503

2025-06-02 (ET)

2025-06-02

07:19:30

Zai Lab presents updated data from Phase 1a/1b trial evaluating ZL-1310

News

2.0

07-18Benzinga

Netflix, BlackSky Technology And Other Big Stocks Moving Lower In Friday's Pre-Market Session

9.0

07-16PRnewswire

Cancer Pipeline Milestones Coming Fast as Regulators Revisit Research Priorities

4.0

06-30Benzinga

Leerink Partners Maintains Outperform on Zai Lab, Raises Price Target to $75

People Also Watch

AWR

American States Water Co

Independent Bank Corp (Massachusetts)

Intuitive Machines Inc

Chesapeake Utilities Corp

Heartland Financial USA Inc

Twist Bioscience Corp

Laureate Education Inc

22.950

USD

-0.17%

FAQ

What is Zai Lab Ltd (ZLAB) stock price today?

The current price of ZLAB is 37 USD — it has increased 6.75 % in the last trading day.

ZLAB

Market Estimates

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Trading Trends

ZLAB News & Events

Events Timeline

News

People Also Watch

FAQ

What is Zai Lab Ltd (ZLAB) stock price today?

What is Zai Lab Ltd (ZLAB)'s business?

What is the price predicton of ZLAB Stock?

What is Zai Lab Ltd (ZLAB)'s revenue for the last quarter?

What is Zai Lab Ltd (ZLAB)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Zai Lab Ltd (ZLAB)'s fundamentals?

How many employees does Zai Lab Ltd (ZLAB). have?

What is Zai Lab Ltd (ZLAB) market cap?